#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	2494	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2201	324.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1465	1465	C	324	C	303	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4070	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4020	303.1	0	.	n	.	0	T695C	SNP	695	695	T	1249	1249	C	306	C	281	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4070	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4020	303.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1891	1891	A	331	A	316	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4070	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4020	303.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2525	2525	C	418	C	382	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4070	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4020	303.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2599	2599	A	438	A	396	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4070	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4020	303.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3151	3151	C	390	C	346	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	472	folP	852	852	100.0	folP.l15.c4.ctg.1	2166	65.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1345	1347	AGC	109;109;108	A;G;C,A,G	101;101;98,1,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	898	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4218	63.8	1	SNP	p	S91F	0	.	.	271	273	TCC	1131	1133	TCC	69;69;69	T;C,G;C	61;64,1;64	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	898	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4218	63.8	1	SNP	p	D95N	0	.	.	283	285	GAC	1143	1145	GAC	71;70;70	G;A;C	65;65;67	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	898	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4218	63.8	1	SNP	p	D95G	0	.	.	283	285	GAC	1143	1145	GAC	71;70;70	G;A;C	65;65;67	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	M16I	NONSYN	46	48	ATG	675	677	ATT	50;50;49	A;T;T	45;43;42	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	D40A	NONSYN	118	120	GAC	747	749	GCC	48;47;46	G;C;C	42;42;41	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	R44H	NONSYN	130	132	CGC	759	761	CAC	45;45;45	C,T;A;C,T	38,1;39;37,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	I73M	NONSYN	217	219	ATC	846	848	ATG	39;39;39	A;T;G	37;38;38	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	A74S	NONSYN	220	222	GCG	849	851	TCG	39;39;39	T;C;G	36;38;38	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	Q75K	NONSYN	223	225	CAA	852	854	AAA	39;39;39	A;A;A	38;38;36	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	A77T	NONSYN	229	231	GCC	858	860	ACG	39;39;39	A;C;G	38;38;36	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	.	MULTIPLE	233	234	CA	862	864	AAA	38;38;38	A;A;A	38;38;37	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	D79N	NONSYN	235	237	GAT	867	869	AAT	38;38;38	A;A;T	37;38;38	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	G83Q	NONSYN	247	249	GGG	879	881	CAA	38;38;38	C;A;A	37;37;38	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	H90R	NONSYN	268	270	CAC	900	902	CGT	38;38;38	C;G;T	37;37;37	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	N110S	NONSYN	328	330	AAC	960	962	AGC	37;37;37	A;G;C	32;34;34	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	V143F	NONSYN	427	429	GTT	1059	1061	TTT	27;27;27	T;T;T	24;23;23	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	A154S	NONSYN	460	462	GCT	1092	1094	TCG	22;21;21	T;C;G	21;19;20	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	D155G	NONSYN	463	465	GAC	1095	1097	GGT	20;19;19	G;G;T,G	20;17;17,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	T161M	NONSYN	481	483	ACG	1113	1115	ATG	18;18;18	A;T;G	17;18;18	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	T169M	NONSYN	505	507	ACG	1137	1139	ATG	18;18;18	A;T;G	18;18;18	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	F178L	NONSYN	532	534	TTC	1164	1166	CTC	17;17;17	C;T;C	16;17;17	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	S183N	NONSYN	547	549	AGT	1179	1181	AAT	17;17;17	A;A;T	17;17;16	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	G195E	NONSYN	583	585	GGG	1215	1217	GAA	16;16;16	G;A;A	16;16;16	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	0	.	p	.	0	C206Q	NONSYN	616	618	TGC	1248	1250	CAG	13;13;13	C;A;G	12;13;12	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	114	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1311	26.0	1	SNP	p	G45D	0	.	.	133	135	GGC	762	764	GGC	45;44;45	G;G;C	40;41;42	mtrR.WHO_Z_01455:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1048	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3551	88.5	1	SNP	p	D86N	0	.	.	256	258	GAC	930	932	GAC	113;112;112	G,T;A,T;C	102,1;102,1;100	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1048	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3551	88.5	1	SNP	p	S87R	0	.	.	259	261	AGT	933	935	AGT	112;112;112	A;G;T	100;104;102	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1048	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3551	88.5	1	SNP	p	S87W	0	.	.	259	261	AGT	933	935	AGT	112;112;112	A;G;T	100;104;102	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1048	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3551	88.5	1	SNP	p	S87I	0	.	.	259	261	AGT	933	935	AGT	112;112;112	A;G;T	100;104;102	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1048	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3551	88.5	1	SNP	p	S88P	0	.	.	262	264	TCC	936	938	TCC	110;110;110	T;C,A;C	105;101,1;105	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	864	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3315	78.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1944	1946	GGC	98;96;96	G;G,C;C	90;86,1;86	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	670	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2924	68.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1582	1584	GCA	88;88;88	G;C,T;A	78;78,1;81	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	670	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2924	68.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1585	1587	ATC	87;87;88	A;T,G;C	80;78,1;79	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	670	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2924	68.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1597	1599	GTG	93;92;91	G;T;G	85;84;83	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	670	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2924	68.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1597	1599	GTG	93;92;91	G;T;G	85;84;83	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	670	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2924	68.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2101	2103	ACC	85;87;86	A,C;C;C	76,1;81;82	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	670	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2924	68.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2155	2157	GCG	78;79;80	G;C;G	72;66;69	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	670	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2924	68.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2155	2157	GCG	78;79;80	G;C;G	72;66;69	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	670	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2924	68.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2278	2280	GGC	73;73;72	G;G;C	63;65;59	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	670	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2924	68.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2287	2289	GGC	74;74;75	G;G;C	62;67;62	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	670	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2924	68.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2305	2307	CCG	72;72;73	C;C,A;G,C	61;61,1;57,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	954	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3514	81.1	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1762	1764	CTG	110;110;111	C;T;G,A	92;96;96,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	504	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2446	61.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	839	839	C	84	C	77	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	42	porB1a	984	297	91.03	porB1a.l6.c4.ctg.1	1277	9.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1005	1007	AAT	7;7;7	A;A;T	6;6;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	42	porB1a	984	297	91.03	porB1a.l6.c4.ctg.1	1277	9.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1008	1010	AAT	7;7;7	A;A;T	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	42	porB1a	984	297	91.03	porB1a.l6.c4.ctg.1	1277	9.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1032	1034	GCA	7;7;7	G;C;A	6;5;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	42	porB1a	984	297	91.03	porB1a.l6.c4.ctg.1	1277	9.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1055	1057	GTA	6;6;6	G;T;A	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	42	porB1a	984	297	91.03	porB1a.l6.c4.ctg.1	1277	9.0	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1064	1064	A	6	A	6	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	430	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	2231	57.5	0	.	p	.	0	I45V	NONSYN	133	135	ATT	785	787	GTT	96;96;96	G;T;T,G	88;87;86,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	430	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	2231	57.5	0	.	p	.	0	T49I	NONSYN	145	147	ACC	797	799	ATC	94;93;94	A;T;C	86;84;87	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	430	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	2231	57.5	0	.	p	.	0	I75V	NONSYN	223	225	ATT	875	877	GTT	98;98;99	G;T;T	96;95;95	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	430	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	2231	57.5	0	.	p	.	0	S89T	NONSYN	265	267	AGC	917	919	ACC	107;107;106	A;C;C,T	98;99;96,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	430	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	2231	57.5	0	.	p	.	0	I98V	NONSYN	292	294	ATC	944	946	GTC	103;103;103	G;T;C	96;95;95	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	430	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	2231	57.5	0	.	p	.	0	S217G	NONSYN	649	651	AGT	1301	1303	GGT	86;85;85	G;G;T	77;75;76	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	430	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	2231	57.5	1	SNP	p	G120K	1	.	.	358	360	AAG	1010	1012	AAG	106;106;106	A;A;G	93;92;91	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	430	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	2231	57.5	1	SNP	p	N121D	0	.	.	361	363	AAC	1013	1015	AAC	107;106;107	A;A;C	94;90;89	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	430	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	2231	57.5	1	SNP	p	A121N	1	.	.	361	363	AAC	1013	1015	AAC	107;106;107	A;A;C	94;90;89	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1500	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5367	83.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2271	2273	AAT	93;93;93	A;A;T	83;84;81	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	166	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1562	31.1	1	SNP	p	V57M	1	.	.	169	171	ATG	685	687	ATG	58;58;57	A;T;G	50;51;50	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
